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A stereotyped environmental stress response
to a wide range of stressors and toxicants
was ﬁrst demonstrated in yeast (Gasch et al.
2000) and has subsequently been observed
in a variety of mammalian cell models
(Heinloth et al. 2003; Morgan et al. 2002;
Murray et al. 2004; Park et al. 2002; Sesto
et al. 2002; Weigel et al. 2002). We have
previously used DNA microarray experi-
ments to characterize the transcriptional
responses of four breast cell lines to the
chemotherapeutics doxorubicin (DOX) and
5-fluorouracil (5FU); these cell lines
included two human telomerase reverse
transcriptase (hTERT–immortalized human
mammary epithelial (HME) cell lines and
two tumor-derived cell lines of luminal
epithelial origin (MCF-7 and ZR-75-1). A
general stress response was shown to pre-
dominate when these cells were treated with
DOX and 5FU (Troester et al. 2004). All
four cell lines repressed genes involved in
cell growth and induced DNA-damage
response and xenobiotic metabolism genes,
but there were differences in the general
stress responses depending upon the cell
type of origin of the cell line.
The mechanisms of action of DOX and
5FU are distinct. DOX is a topoisomerase
IIA (TOP2A) poison. TOP2A is a nuclear
enzyme that transiently breaks and rejoins
the phosphodiester backbone of both
strands of the double helix. As such, it is
vital for DNA replication, chromosome
segregation, and maintenance of chromo-
some structure. In previous studies (Tewey
et al. 1984), DOX formed a stable ternary
complex with DNA and TOP2A, thereby
inhibiting the normal function of the
enzyme. The complexed enzyme is unable
to re-ligate DNA so complex formation
increases DNA strand breaks. TOP2A is
highly expressed during S-phase, but
TOP2A poisoning causes cell-cycle arrest
in G2-M. The commonly used chemother-
apeutic 5FU has several known mecha-
nisms of action that distinguish it from
DOX. 5FU covalently binds to thymidy-
late synthase, preventing de novo produc-
tion of thymidine. It also incorporates into
DNA and RNA (Longley et al. 2003;
Pizzorno et al. 2000). The importance of
each of these 5FU-mediated disruptions in
cellular metabolism varies across cell lines
and patients, but current studies emphasize
the role of thymidylate synthase inhibition
(Banerjee et al. 2002; Longley et al. 2003;
Peters et al. 2002). Thymidylate synthase is
highly expressed during S-phase, and its
inhibition is thought to cause cell-cycle
arrest in S-phase.
Using microarrays, it is often possible
to identify unique patterns associated with
specific toxicants in addition to common
patterns of response. We used our panel of
treated breast cell lines (Troester et al.
2004) to identify toxicant-specific expres-
sion signatures for DOX and 5FU. Cell
lines derived from breast basal-like and
luminal epithelium exhibited distinct toxi-
cant-specific patterns of response. Using
two statistical methods for class prediction,
we then identiﬁed sets of genes that distin-
guished DOX- and 5FU-treated cells and
used these lists to predict the mechanism of
etoposide (ETOP), a drug that is mecha-
nistically similar to DOX.
Materials and Methods
Cells and Cell Culture Conditions
ME16C and HME-CC cells, two basal-like
hTERT-immortalized HME cell lines
described by Torester et al. (2004), were gifts
from J.W. Shay at the University of Texas
Southwestern Medical Center at Dallas
(Dallas, TX) and C. Counter at Duke
University Medical Center (Durham, NC),
respectively. ME16C cells and HME-CC
cells were maintained in mammary epithelial
growth media (Cambrex Bio Science
Walkersville Inc., Walkersville, MD).
MCF-7 cells (a gift from F. Tamanoi,
University of California at Los Angeles) and
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Global gene expression profiling has demonstrated that the predominant cellular response to a
range of toxicants is a general stress response. This stereotyped environmental stress response com-
monly includes repression of protein synthesis and cell-cycle–regulated genes and induction of
DNA damage and oxidative stress–responsive genes. Our laboratory recently characterized the gen-
eral stress response of breast cell lines derived from basal-like and luminal epithelium after treat-
ment with doxorubicin (DOX) or 5-fluorouracil (5FU) and showed that each cell type has a
distinct response. However, we expected that some of the expression changes induced by DOX and
5FU would be unique to each compound and might reﬂect the underlying mechanisms of action of
these agents. Therefore, we employed supervised analyses (signiﬁcance analysis of microarrays) to
identify genes that showed differential expression between DOX-treated and 5FU-treated cell lines.
We then used cross-validation analyses and identiﬁed genes that afforded high predictive accuracy
in classifying samples into the two treatment classes. To test whether these gene lists had good pre-
dictive accuracy in an independent data set, we treated our panel of cell lines with etoposide, a
compound mechanistically similar to DOX. We demonstrated that using expression patterns of
100 genes we were able to obtain 100% predictive accuracy in classifying the etoposide samples as
being more similar in expression to DOX-treated than to 5FU-treated samples. These analyses also
showed that toxicant-specific gene expression patterns, similar to general stress responses,
vary according to cell type. Key words: breast cancer, class prediction, doxorubicin, etoposide,
5-fluorouracil, gene expression, microarrays. Environ Health Perspect 112:1607–1613 (2004).
doi:10.1289/txg.7204 available via http://dx.doi.org/ [Online 14 September 2004]ZR-75-1 cells (American Type Culture
Collection, Manassas, VA) were maintained
in RPMI 1640 with L-glutamine (GIBCO,
Carlsbad, CA) supplemented with 10% fetal
bovine serum (Sigma Chemical Co.,
St. Louis, MO) and 50 U/mL penicillin and
50 U/mL streptomycin (GIBCO). All cell
lines were tested for mycoplasma by the
University of North Carolina at Chapel Hill
Tissue Culture Facility before experiments
were conducted and at regular intervals
thereafter. Cells were maintained at 37°C
and 5% carbon dioxide.
Cytotoxicity Assay
A mitochondrial dye conversion assay (Cell
Titer 96; Promega Corp., Madison, WI)
was used to measure cell viability after treat-
ment. This assay was conducted according
to manufacturer’s instructions, with modiﬁ-
cation as follows. Briefly, 5,000 cells were
seeded per well of a 96-well plate. Cells were
allowed to adhere overnight, and then
media were replaced with fresh media
containing a range of drug doses (DOX,
0–1 µM; ETOP, 0–500 µM; 5FU,
0–10 mM). After 36 hr of drug treatment,
15 µL of tetrazolium dye solution were
added, and cells were incubated for 1 hr at
37°C before adding stop solution. Dye con-
version products were solubilized in a
humidified chamber overnight, and
absorbance was measured at 570 nm (minus
background absorbance at 650 nm). The
50% inhibitory concentration (IC50) for
36 hr of treatment with each drug in each
cell line was estimated using nonlinear
regression (SAS Statistical Software,
version 8; SAS Institute Inc., Cary, NC) as
described previously (Troester et al. 2004).
Collection of mRNA for Microarray
Experiments
Cell lines were grown in 150-mm dishes to
70–80% conﬂuence and then treated for 12,
24, or 36 hr with toxicant at the IC50 con-
centration. The cells were harvested by scrap-
ing, and cell lysates were enriched for mRNA
using a Micro-FastTrack kit (Invitrogen
Corp., Carlsbad, CA). The reference RNA
was generated by harvesting mRNA from
each cell line at 80% conﬂuence and pooling
four such harvests (i.e., four MCF-7 harvests
were pooled and served as reference mRNA
for all MCF-7 experiments).
Microarray Experiments
To synthesize labeled cDNA, reverse
transcription reactions were carried out
using 3 µg of mRNA as described previously
(Perou et al. 2000; Troester et al. 2004).
Briefly, 5FU, DOX, ETOP, and vehicle
controls were labeled with Cy5–dUTP, and
the pooled cell line control was labeled with
Cy3–dUTP. The Cy3- and Cy5-labeled
samples were combined and hybridized
overnight at 65°C to a custom oligonu-
cleotide microarray created in the University
of North Carolina at Chapel Hill Genomics
Core Facility. Arrays were spotted with
Compugen (Jamesburg, NJ) human oligos
representing approximately 22,000 genes.
Two replicate arrays for each sample were
selected for subsequent analysis. All micro-
array raw data tables are available at the UNC
Microarray Database (https://genome.unc.
edu/) and have been deposited in the Gene
Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo/) under accession number
GSE1647 (submitted by C. Perou). 
Signiﬁcance Analysis of Microarrays
Genes that were signiﬁcantly up- or down-
regulated were identiﬁed using Significance
Analysis of Microarrays (SAM; Tusher et al.
2001). For the SAM analysis, data were
excluded for genes that did not have mean
intensity greater than twice the median back-
ground for both the red and green channel
in at least 70% of the experiments. The log2
of the median red intensity over median
green intensity was calculated for each gene.
Missing data were imputed using the SAM
Add-In for Excel (Microsoft Corp.,
Redmond, WA) plug-in with 100 permuta-
tions and k-nearest neighbors (KNN) with
k = 10. For each cell line, 12-, 24-, and 36-hr
DOX–treated arrays were coded as one class
and were compared the 12-, 24-, and 36-hr
5FU–treated arrays using a two-class,
unpaired SAM. Delta values were adjusted to
obtain the largest gene list with a false dis-
covery rate < 5%. The effects of adding
media would be present in the signatures of
both compounds and would not be identi-
fied as significantly associated with either
toxicant. However, because DOX was solu-
bilized in water and ETOP and 5FU were
solubilized in dimethyl sulfoxide (DMSO),
we also collected mRNA from each cell line
treated with DMSO only for 12, 24, or
36 hr (data not shown). We compared these
DMSO-treated samples with sham (media
only) samples for these same time points
using SAM. The lowest false discovery rate
obtained was 15.3% (15 genes with
2.29 false signiﬁcant), which shows that the
toxicant-specific changes we detected are
highly unlikely to reflect changes induced
by vehicle.
Class Prediction
The number of genes needed to distinguish
DOX and 5FU samples were identified
using 10-fold cross-validation (CV) analysis
using Prediction Analysis of Microarrays
(PAM) and a KNN classifier. The KNN
metric uses the Euclidian distance to
determine the similarity of a sample to its k
nearest sample neighbors. To select genes
for the KNN method, we used a gene selec-
tion method that was first described by
Dudoit and Fridlyand (2002); the KNN
genes were identified in the training set
according to the ratio of between-group to
within-group sums of squares (Dudoit and
Fridlyand 2002). The n top-ranked genes
were used for each round of CV. The size
of the gene subset was increased for
subsequent rounds of CV. The set of
n top-ranked genes that gave the highest
average prediction accuracy during CV was
also determined and reported. Gene selec-
tion using PAM was completed as described
previously (Tibshirani et al. 2002). Genes
were selected that yielded the greatest pre-
dictive accuracy in classifying DOX versus
5FU using a 10-fold CV analysis.
For class prediction, we performed a
10-fold CV analysis to iteratively optimize
the list of genes and to determine predic-
tion accuracies. Each round of CV would
begin by splitting the samples into a train-
ing set (90% of the samples) and a test set
(10% left-out samples), with gene selection
and training being performed on the 90%
and then used to predict the status of the
withheld 10%. This was repeated 10 times,
each time using a different 10% subset and
a different gene set. Our reported predic-
tion accuracies are the average of these
iterative cycles of prediction for the opti-
mized model. The results of all CV
analyses using PAM and KNN are pre-
sented in Supplemental Data, Tables 1–4
(http://ehp.niehs.nih.gov/txg/members/
2004/7204/supplemental.pdf). To indepen-
dently assess the validity of these gene lists,
we used them to predict class for ETOP
samples; this analysis is independent
because the ETOP samples were not used
to train the predictor. The prediction accu-
racy for the ETOP samples are shown in
Tables 2 and 3. For the four-class model,
two samples were misclassified with PAM
(HME-CC 12 hr and ME16C 12 hr) and
two samples were misclassified with
KNN (MCF-7 12 hr and ZR-75-1 36 hr)
yielding the reported prediction accuracies
of 75%.
Clustering of Toxicant-Speciﬁc
Responses
Once gene lists were identified for the
toxicant-speciﬁc responses of each cell line,
hierarchical clustering analysis was conducted
using the program Cluster (version 2.0;
http://rana.lbl.gov/EisenSoftware.htm) to
perform uncentered, average-linkage cluster-
ing; the data were visualized using Treeview
(http://rana.lbl.gov/EisenSoftware.htm; Eisen
and Brown 1999; Eisen et al. 1998). The
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luminal lines (MCF-7 and ZR-75-1) were
combined into a nonredundant list, and
data for these genes were compiled for all
MCF-7 and ZR-75-1 samples. Similarly, the
gene lists for the two basal-like lines (ME16C
and HME-CC) were combined into a non-
redundant list, and data for these genes were
compiled for all HME-hTERT samples. For
clustering and displaying results, data were
excluded for genes that did not have mean
intensity greater than twice the median
background for both the red and green
channels in at least 80% (Figures 1 and 2)
or 70% (Figure 3) of the experiments.
Supplemental Data, Figures 1–3  are (http://
ehp.niehs.nih.gov/txg/members/2004/7204/
supplemental.pdf) the complete cluster
diagrams that correspond to Figures 1–3.
Results
Toxicant-Speciﬁc Transcriptional
Responses
To investigate the toxicant-specific
responses of four breast cell lines treated
with chemotherapeutics, we collected
mRNA from MCF-7, ZR-75-1, ME16C,
and HME-CC cell lines after treating with
DOX and 5FU at doses that produced
similar levels of toxicity (IC50) across all
four lines.
The IC50 was estimated from mitochon-
drial dye conversion assay results after 36 hr
treatments with 5FU and DOX. The IC50
values and their 95% conﬁdence intervals are
shown in Table 1. For DOX and 5FU, the
doses selected are consistent with physiologic
doses expected in patients receiving treat-
ment with DOX (Gewirtz 1999) or 5FU
(Peters et al. 1993; Terret et al. 2000). This
experimental design was aimed at defining
the steady-state transcriptional response of
these cell lines to toxicants and on deﬁning
chemotherapeutic-specific responses that
were consistent over time. By combining
12-, 24-, and 36-hr–treated experiments into
a single class for all supervised analyses, we
identiﬁed genes that had a consistent pattern
of expression across all three time points.
These genes are the most likely to be consis-
tent with in vivo experiments or patient sam-
ples, where it is difﬁcult to assess how long a
tissue sample has been exposed to a toxic
agent. Although we did not specifically
search for temporal variation in our SAM
analyses, some temporal variation in gene
expression can be observed in the clusters.
Toxicant-Speciﬁc Responses in
Luminal Cell Lines
A large list of genes was identified for
MCF-7 (974 genes with 44.7 false signifi-
cant) and for ZR-75-1 (883 genes with
41.6 false significant) when supervised
analyses were conducted to compare DOX-
versus 5FU-treated samples. Hierarchical
clustering analysis of the MCF-7 and
ZR-75-1 experiments using the combined
and nonredundant gene lists showed dis-
tinct responses for each toxicant (Figure 1
and Supplemental Data, Figure 1). The
primary dendrogram branches for DOX-
treated and 5FU-treated experiments were
subdivided into MCF-7 and ZR-75-1
branches (Figure 1B); this suggests that
most variation in these genes is attributable
to the toxicant, but that cell lines also
contribute to the variation. A total of
191 genes (77 down-regulated and 114 up-
regulated) appeared on the SAM lists for
both MCF-7 and ZR-75-1. However, there
are many more genes that show qualitative
similarity in the toxicant-speciﬁc responses
of MCF-7 and ZR-75-1 cells (Figure 1 and
Supplemental Data, Figure 1) than are cap-
tured using the strict SAM analysis.
Figure 1D shows a cluster of genes that is
up-regulated in MCF-7 cells after DOX
treatment but is down-regulated in
ZR-75-1 cells after both treatments;
thymidylate synthase (TYMS) is included
in this cluster. Recent studies have shown
that thymidylate synthase, the target of
Toxicogenomics | Toxicant-specific signatures in breast cell lines
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Figure 1. Gene expression patterns for genes that distinguish between DOX- and 5FU-treated luminal cells
(MCF-7 and ZR-75-1). Hierarchical clustering analysis was conducted using 13 DOX-treated and 13 5FU-
treated samples. Data from the union of the genes identiﬁed by SAM for MCF-7 and ZR-75-1 were identi-
ﬁed and combined into a nonredundant list, and the compressed cluster is shown in A (complete cluster
is available in Supplemental Data, Figure 1). Colored bars on right side of A illustrate the location of clus-
ters shown in C–G. The dendrogram in B shows that the samples clustered into two groups according to
treatment (DOX experiments labeled in red, 5FU experiments labeled in blue), but within each treatment
branch, cell line–speciﬁc branches are also identiﬁable. Gene names and accession numbers are from
Unigene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db = unigene). Gene names and accession
numbers highlighted in red are discussed in text.5FU, binds p53 mRNA and regulates the
expression of p53 at the translational level
(Chu et al. 1999; Ju et al. 1999). This is
relevant because p53 expression is slightly
induced by DOX in MCF-7 cells but not
in ZR-75-1 cells or by 5FU treatment in
either cell line (Figure 1E).
The gene set in Figure 1E also shows
that several other genes had slightly higher
expression in MCF-7 cells treated with
DOX, and that these genes were typically
repressed in ZR-75-1 cells. For example, the
mismatch repair gene mutL homolog 1
(MLH1) was unchanged by DOX, and
N-methylpurine-DNA glycosylase (MPG), a
base excision repair gene, was repressed by
5FU. Both DOX and 5FU can cause DNA
damage, but differences in the profiles of
damage induced by each compound may
account for differently regulated repair
enzymes. Cyclin E1 (CCNE1) was also
slightly induced in DOX-treated MCF-7
cells, as has been shown in previous studies
(Arooz et al. 2000). CCNE1 and v-myb
myeloblastosis viral oncogene homolog
avian-like 2 (MYBL2) are important genes
involved in the G1–S transition and are
transcriptional targets of E2F (Yasui et al.
2003).
Figure 1F shows that ZR-75-1 cells
have a unique response to DOX compared
with MCF-7 cells and 5FU-treated cells.
In concordance with increased E-cadherin
(CDH1) expression shown in this cluster,
an increase in (CDH1) mRNA (and
CDH1–mediated cell–cell adhesion) has
been shown previously in another breast
cancer cell line after treatment with DOX
(Yang et al. 1999). Cyclin G2 (CCNG2)
was also induced in ZR-75-1 cells treated
with DOX. This cyclin is inducible by
DNA damage in a p53-independent
manner (Bates et al. 1996).
Figure 1C and G shows clusters of
genes that are induced by 5FU in both cell
lines and either unchanged or only mod-
estly changed in DOX-treated lines. For
example, inhibitor of DNA binding 3
(ID3) (Figure 1C) and ID1 (Figure 1G)
were strongly induced only in the 5FU-
treated samples. The Id proteins control
cellular differentiation and cell-cycle pro-
gression by preventing transcription factors
from binding DNA (Norton et al. 1998).
These proteins target basic helix–loop–helix
proteins that regulate cell-type–speciﬁc and
cell-cycle–regulatory gene expression (Lassar
et al. 1994); however, the role of these pro-
teins in the response to 5FU is not known.
Toxicant-Speciﬁc Responses 
in Basal-Like Cell Lines
A smaller list of toxicant-specific genes
was identified for ME16C (76 genes with
3.7 false significant) and HME-CC
(193 genes with 8.6 false significant) cells
when SAM was used to compare DOX-
treated with 5FU-treated samples.
Hierarchical clustering using the com-
bined and nonredundant gene lists for
these two cell lines showed that there were
distinct responses by toxicant (Figure 2
and Supplemental Data, Figure 2).
However, the primary dendrogram branch
for 5FU-treated basal-like cell lines also
included two early time points for DOX-
treated ME16C (Figure 2B). The 12-hr
ME16C time point has many gene expres-
sion changes in response to treatment
(Troester et al. 2004), but this time point
does not exhibit the same toxicant-specific
signature as do the 24- and 36-hr time
points. These temporal differences likely
account for the grouping of toxicant-spe-
cific signatures in Figure 2. As we have
also seen in our previous study of the gen-
eral stress response of these cell lines, the
temporal response to these two toxicants
varies by cell line.
Figure 2C shows a cluster of genes that
is up-regulated in DOX-treated basal-like
cell lines but down-regulated in 5FU-
treated basal-like cells. These genes differ in
both magnitude and direction of change. A
number of these genes play a role in medi-
ating DNA repair, including ubiquitin-
conjugating enzyme E2A (UBE2A), which
is a member of the RAD6 pathway that
uses ubiquitin conjugation to control DNA
damage–induced mutagenesis (Stelter and
Ulrich 2003). Similarly, DNA polymerase
delta is known to repair single-strand DNA
interruptions produced during the process
of base excision repair (Ho and Satoh
2003). Cell division cycle 25B (CDC25B),
an important regulator of mitosis, is also
found in this cluster.
The cluster in Figure 2D contains
several mitochondrial genes (indicated in
red). The altered expression of mitochon-
drial genes might be expected based on a
recent study that demonstrated that
anthracyclines, such as DOX, impair
cellular respiration (Souid et al. 2003).
Figure 2E consists of a set of genes that is
clearly enriched for ribosomal proteins.
Disruption of protein biosynthesis has been
associated with alterations in the cell cycle
and cell growth (Ruggero and Pandolfi
2003). Five ribosomal proteins are high-
lighted in red, and AL110170 is a hypo-
thetical protein with 65% homology to
ribosomal protein L22. The genes for these
proteins are induced in the DOX-treated
Toxicogenomics | Troester et al.
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Figure 2. Gene expression patterns for genes that distinguish between DOX- and 5FU-treated basal-like
cells (ME16C and HME-CC). Hierarchical clustering analysis was conducted using 13 DOX-treated and
12 5FU-treated samples. Data from the union of the genes identiﬁed by SAM for ME16C and HME-CC were
identified and combined into a nonredundant list, and the compressed cluster is shown in A (complete
cluster available in Supplemental Data, Figure 2). Colored bars in A illustrate the location of clusters
shown in C–E. The dendrogram in B shows that the samples clustered into two groups according to treat-
ment (DOX experiments labeled in red, 5FU experiments labeled in blue); however, there early time points
for DOX-treated ME16C samples clustered with the 5FU-treated samples. Gene names and accession
numbers are from Unigene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db = unigene). Gene names
and accession numbers highlighted in red are discussed in text.HME-CC cell line after 36 hr but are
repressed in the ME16C cells at this and all
other time points assayed.
Class Prediction and Sample
Classiﬁcation for ETOP-Treated
Samples
Having identified a number of genes that
distinguish DOX- from 5FU-treated breast
cell lines using SAM, we next performed
class prediction analyses to assess whether
these differences could be used to classify
an independent data set collected using the
same four cell lines. Because SAM does not
perform sample classification, we used
10-fold CV with PAM (Tibshirani et al.
2002) and a KNN metric based upon the
work of Dudoit and Fridlyand (2002). CV
was implemented to optimize the number
of neighbors (k) and the number of genes
for KNN, and to optimize the shrinkage
parameter (∆) for PAM. Parameters were
selected that generated the highest CV
accuracy (internal validation) when
distinguishing the DOX- and 5FU-treated
samples. Then, using the optimized mod-
els, we made predictions on a test set of
ETOP-treated samples (external valida-
tion). (Note that because CV excludes sam-
ples and the final model using the
optimized parameters does not, the ∆-value
selected during CV with PAM may corre-
spond to a different number of genes dur-
ing prediction. However, the number of
genes selected in CV is held constant for
the KNN-based prediction.)
We expected that because ETOP and
DOX both inhibit TOP2A, their resulting
transcriptional profiles should be similar.
Therefore, we considered ETOP samples
correctly classiﬁed if they were classiﬁed as
DOX. In a two-class analysis (DOX vs.
5FU), we obtained a high degree of CV
accuracy (80–98%) during training and a
high degree of predictive accuracy (100%)
in assigning the ETOP experiments as more
similar to DOX than 5FU (Table 2).
However, when we attempted to further
subclassify the DOX and 5FU samples
according to cell-type (basal-like–DOX vs.
basal-like–5FU vs. luminal-DOX vs. lumi-
nal-5FU), our CV (76–80%) and predic-
tion (75%) accuracies were diminished
(Table 3). The errors in four-class predic-
tion occurred in the 12-hr basal-like sam-
ples. This is not surprising based on our
clustering results in Figure 2, where the
early time points in one of the basal-like cell
lines appeared distinct from later points.
To visualize the expression differences
from the two-class DOX versus 5FU pre-
dictor using Euclidian KNN, we took these
samples and the 100 gene set shown to be
98% accurate in prediction and performed
hierarchical clustering analysis (Figure 3
and Supplemental Data, Figure 3). The
similarities between the ETOP and DOX
samples were observable across this gene
set. This analysis showed two separate
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Figure 3. Gene expression patterns for genes selected for a two-class (DOX vs. 5FU) predictive model. Hierarchical clustering analysis was conducted using
26 DOX-treated, 25 5FU-treated samples, and 8 ETOP-treated samples. Data from the genes identiﬁed using a KNN classiﬁer for DOX-treated versus 5FU-treated
experiments are displayed in the compressed cluster shown in A (complete cluster available in Supplemental Data, Figure 3). Colored bars in A illustrate the loca-
tion of clusters shown in C–E. The dendrogram in B shows that the samples clustered into two groups according to treatment (DOX experiments labeled in red,
5FU experiments labeled in blue and ETOP experiments labeled in orange. Gene names and accession numbers are from Unigene (http://www.ncbi.nlm.
nih.gov/entrez/query.fcgi?db = unigene). Gene names and accession numbers highlighted in red are discussed in text.dendrogram branches in Figure 3B, with
one branch containing all of the 5FU sam-
ples and the other containing the ETOP
and DOX samples. Some of the genes iden-
tiﬁed in the earlier supervised analysis were
recapitulated in this predictive gene set.
Notably, ID3 appears in Figure 3C and p53
appears in Figure 3E. An interesting cluster
of genes that was more strongly induced in
DOX and ETOP samples appears in
Figure 3D, which includes cathepsin L
(CTSL) and cystatin C (CST3). The activity
of the cysteine protease CTSL is regulated
by the cystatins (a family of cysteine pro-
teinase inhibitors), and their imbalance is
associated with increased invasiveness and
development of the malignant cell pheno-
type (Kos and Lah 1998).
Discussion
Most changes that occur in gene expression
after treatment with either DOX or 5FU
are indicative of a general stress response
(Troester et al. 2004). However, in the
work presented here, we were interested in
identifying the toxicant-specific transcrip-
tional responses to DOX and 5FU in
breast epithelial cell lines. We conducted
several different supervised analyses to
identify genes that distinguished between
DOX and 5FU and were able to define
toxicant-specific profiles. Using SAM, we
found that each cell type (basal-like or
luminal-derived) and each cell line had
unique responses to DOX and 5FU.
Similar to our previous observations for
general stress responses (Troester et al.
2004), we found that the luminal cell lines
responded to treatment by regulating a
large number of genes, whereas the basal-
like cell lines had many fewer expression
changes in response to treatment. In addi-
tion the basal-like cell lines showed greater
temporal variation in expression than did
the luminal lines. Some of the genes that
comprised the general stress signature for
each cell type were also found to have toxi-
cant-specific expression in our supervised
analyses. This occurred in cases where
both DOX and 5FU induced or repressed
gene expression relative to shams, but
where one treatment induced a change
with greater magnitude. For example, the
expression of CST3 was induced more
strongly byTOP2A inhibitors than by 5FU
(Figure 3D) but was induced in both treat-
ments relative to sham (Troester et al.
2004). Thus, CST3 is a general stress
response gene with a toxicant-speciﬁc gene
expression signature.
Toxicant-specific expression responses
in our data were corroborated by published
reports with these drugs in the same or
similar cell lines. For example, impaired
cellular respiration after DOX treatment
has been previously reported (Souid et al.
2003), and in our data, mitochondrial gene
expression was altered (Figure 2D). Earlier
studies have shown that 5FU’s target pro-
tein thymidylate synthase can bind p53
(Chu et al. 1999; Ju et al. 1999), and we
show that p53 mRNA levels are reduced in
our 5FU-treated cells. Thus, many of the
gene expression changes that we identified
recapitulated previous ﬁndings. However, a
number of significant changes that were
not anticipated based on the literature were
identiﬁed and likely have functional impor-
tance. For example, the induction of ID1
and ID3 has not previously been reported
for 5FU. The importance of the Id proteins
has only recently begun to be investigated
(Norton et al. 1998); our findings suggest
that these pathways may be responsive to
toxicant treatment and warrant further
investigation.
In addition to characterizing the toxicant-
speciﬁc changes by cell line and cell type, we
used toxicant-speciﬁc gene lists to make pre-
dictions on a third toxicant (ETOP) that is
believed to have a similar mechanism of
action as one of the training toxicants
(DOX). Successfully classifying similar com-
pounds establishes that observed transcrip-
tional responses reﬂect an underlying mode
of action. Using as few as 100 genes, we
were able to classify ETOP samples as being
similar to DOX treated samples with 100%
predictive accuracy. This predictive accuracy
was reduced to 75% when we attempted to
further subclassify the DOX and 5FU sam-
ples according to cell type of origin.
However, considering that with a four-class
model, the likelihood of correctly classifying
samples by chance is only 25% (compared
with 50% for a two-class model), the four-
class model still performs very well. The
samples that were misclassiﬁed included the
early time points in basal-like cell lines,
which is consistent with our previous ﬁnd-
ings that the basal-like cell lines have a dis-
tinct expression proﬁles at 12 hr compared
with their 24- and 36-hr time points
(Troester et al. 2004).
We have used computational analyses
to demonstrate that distinct transcriptional
patterns can be identified for mechanisti-
cally dissimilar compounds and that toxi-
cants with similar mechanisms can be
classified accordingly. We selected two
compounds with distinct mechanisms to
train our model and a test compound with
a mechanism similar to one of the training
compounds. These kinds of mechanistic
analyses are critical for predictive toxicol-
ogy using gene arrays. Many studies in the
ﬁeld of toxicogenomics are aimed at popu-
lating databases with expression data for
diverse toxicants with known mechanisms
of action (Hamadeh et al. 2002). These
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Table 1. Estimated IC50 for 5FU, DOX, and ETOP based on mitochondrial dye conversion assay.a,b
Cell line IC50
c Treatment dosec
5FU MCF-7 0.34 (0.13–0.55) 0.3
ZR-75-1 3.3 (2.8–3.7) 3.0
ME16C 0.064 (0.055–0.074) 0.06
HME-CC 0.011 (0.009–0.013) 0.01
DOX MCF-7 0.86 (0.74–0.97) 0.9
ZR-75-1 0.43 (0.37–0.50) 0.4
ME16C 0.52 (0.49–0.54) 0.5
HME-CC 0.16 (0.14–0.18) 0.2
ETOP MCF-7 35 (30–40) 40
ZR-75-1 26 (8.6–43) 30
ME16C 21 (18–23) 20
HME-CC 6.1 (5.6–6.7) 10
aValues in parentheses represent 95% conﬁdence intervals. bPartially adapted from Troester et al. (2004); IC50 values for
5FU and DOX were previously reported. cDoses for 5FU are in millimolar (mM); those for DOX and ETOP, micromolar (µM).
Table 2. Two-class CV and prediction accuracy for ETOP samples.
CV accuracy Prediction accuracy
Method PAM KNNa PAM KNNa
No. 2,460 (2.75)b 100 279 (2.75)b 100
Accuracy 80% 98% 100% 100%
ak = 11. b∆-Value is shown in parentheses.
Table 3. Four-class CV and prediction accuracy for ETOP samples.
CV accuracy Prediction accuracy
Method PAM KNNa PAM KNNa
No. 652 (3.5)b 100 465 (3.5)b 100
Accuracy 76% 80% 75% 75%
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databases can then be used to infer mecha-
nism of action for new compounds. Our
data show that this approach is feasible and
identifies many new genes and pathways
that are important in the response to these
toxicants.
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